Brief: Calliditas Announces Seven-Year Orphan Drug Exclusivity For Tarpeyo
06/03/2024 07:19
March 6 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* CALLIDITAS ANNOUNCES AN ADDITIONAL SEVEN YEAR ORPHAN DRUG
EXCLUSIVITY PERIOD FOR TARPEYO®
* FDA HAS GRANTED AN ORPHAN DRUG EXCLUSIVITY PERIOD OF SEVEN
YEARS
FOR TARPEYO®, EXPIRING IN DECEMBER 2030
Source text for Eikon: ID:nWkrSlrf4
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations